Facebook
Twitter
LinkedIn
Forward
Use of SGLT2 Inhibitors and the NS-MRA with RAS Inhibitors to Slow DKD Progression
Use of SGLT2 Inhibitors and the NS-MRA with RAS Inhibitors to Slow DKD Progression
- Background and Burden of CKD
- SGLT-2 Inhibitors in CKD: Rationale, Data, and Perspectives
- GLP-1 RAs in CKD
- Non-Steroidal MRAs in CKD: Rationale, Data, and Interpretation
Date of Last Review: 6/1/23
Additional Information
Available Credit
- 0.50 ABIM MOC and AMA PRA Category 1 Credit™
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation